Literature DB >> 15452399

Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp.

Lorenzo Drago1, Elena De Vecchi, Lucia Nicola, Alberto Colombo, Anna Guerra, Maria Rita Gismondo.   

Abstract

BACKGROUND: Combination therapy is used to widen the antimicrobial spectrum, minimize toxicity and prevent the emergence of resistant mutants.
METHODS: Synergy between levofloxacin or ciprofloxacin and ceftazidime, cefepime, imipenem, piperacillin-tazobactam and amikacin was evaluated by checkerboard assay with 55 strains and by time-kill curves with 8 strains of Pseudomonas aeruginosa and Acinetobacter spp.
RESULTS: In the checkerboard assay, synergy and additivity were the most frequent effects observed among all the combinations against P. aeruginosa and Acinetobacter spp., with no significant differences between the two fluoroquinolones. No antagonism was observed. In the time-kill curves, synergy was evidenced against all the tested strains, at least for one combination at one of the time points considered. Levofloxacin and ciprofloxacin combined with ceftazidime, as well as levofloxacin plus amikacin, were synergistic for all the strains tested.
CONCLUSION: Combinations of fluoroquinolones with beta-lactams or amikacin show an enhanced activity against P. aeruginosa and Acinetobacter spp.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452399     DOI: 10.1159/000081033

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

1.  Ciprofloxacin-Mediated Mutagenesis Is Suppressed by Subinhibitory Concentrations of Amikacin in Pseudomonas aeruginosa.

Authors:  Estela Ynés Valencia; Fernanda Esposito; Beny Spira; Jesús Blázquez; Rodrigo S Galhardo
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

2.  In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.

Authors:  Shigeharu Oie; Yumi Fukui; Masaya Yamamoto; Yuki Masuda; Akira Kamiya
Journal:  BMC Infect Dis       Date:  2009-08-10       Impact factor: 3.090

Review 3.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 4.  Treatment options for multidrug-resistant Acinetobacter species.

Authors:  Jacob Gilad; Yehuda Carmeli
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.

Authors:  Devrim Dundar; Metin Otkun
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

6.  In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa.

Authors:  Vladimir Chachanidze; Aixa Curbelo-Irizarry; Deborah Ashcraft; George Pankey
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-11-08

7.  In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.

Authors:  Seongman Bae; Min-Chul Kim; Su-Jin Park; Hee Sueng Kim; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim; Yong Pil Chong
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.